暂无中文译文，显示英文原文。
#SCLC #lungcancer #ESMO26 @myESMO
437 浏览 · 9 赞 · 4 转发 · 0 回复
Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer
https://esmocongress.esmo.orgFirst-line BAT8008 (TROP2-ADC) plus BAT1308 (anti-PD-1) for advanced NSCLC: Results from a multicenter phase 2 study
https://esmocongress.esmo.orgCharacterizing resistance mechanisms and predictors of early progression and long-term response to lorlatinib: Circulating tumor DNA (ctDNA) analyses from the CROWN study
https://esmocongress.esmo.orgOverall survival (OS) analysis of telisotuzumab adizutecan in patients (pts) with nonsquamous non-small cell lung cancer (NSQ NSCLC): Phase 1 first-in-human study
https://esmocongress.esmo.orgPhase 2 trial of the PD-1/VEGF bispecific antibody, PF-08634404 (SSGJ-707), plus chemotherapy (chemo) in advanced NSCLC: Updated results
https://esmocongress.esmo.orgFirst-line (1L) olomorasib + pembrolizumab in KRAS G12C-mutant NSCLC: Updated results from LOXO-RAS-20001 and SUNRAY-01
https://esmocongress.esmo.org@dr_yakupergun @SuyogCancer @myESMO @OncBrothers @KolPulseAI In my view, your opinions regarding DeLLphi-305 and IMforte are very sensible and very intelligent.Congrats! Unfortunately, #Tarlatamab is not for every patient, it cannot be administered in every setting, and it is not the most economical option. This must be taken into account.在 X 查看被引用的帖子
来源：FJ ⭐️⭐️+⭐️ · x.com